These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 11799484)

  • 1. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
    Jain A; Kashyap R; Demetris AJ; Eghstesad B; Pokharna R; Fung JJ
    Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
    Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
    Nelson DR; Soldevila-Pico C; Reed A; Abdelmalek MF; Hemming AW; Van der Werf WJ; Howard R; Davis GL
    Liver Transpl; 2001 Dec; 7(12):1064-70. PubMed ID: 11753908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report.
    Jain AB; Hamad I; Rakela J; Dodson F; Kramer D; Demetris J; McMichael J; Starzl TE; Fung JJ
    Transplantation; 1998 Nov; 66(10):1395-8. PubMed ID: 9846530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
    Klintmalm GB; Davis GL; Teperman L; Netto GJ; Washburn K; Rudich SM; Pomfret EA; Vargas HE; Brown R; Eckhoff D; Pruett TL; Roberts J; Mulligan DC; Charlton MR; Heffron TG; Ham JM; Douglas DD; Sher L; Baliga PK; Kinkhabwala M; Koneru B; Abecassis M; Millis M; Jennings LW; Fasola CG
    Liver Transpl; 2011 Dec; 17(12):1394-403. PubMed ID: 21850690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
    Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation.
    Kornberg A; Küpper B; Tannapfel A; Hommann M; Scheele J
    Int Immunopharmacol; 2005 Jan; 5(1):107-15. PubMed ID: 15589468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report.
    Jain A; Kashyap R; Dodson F; Kramer D; Hamad I; Khan A; Eghestad B; Starzl TE; Fung JJ
    Transplantation; 2001 Sep; 72(6):1091-7. PubMed ID: 11579306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.
    Humar A; Crotteau S; Gruessner A; Kandaswamy R; Gruessner R; Payne W; Lake J
    Clin Transplant; 2007; 21(4):526-31. PubMed ID: 17645714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.
    Berenguer M; Aguilera V; San Juan F; Benlloch S; Rubin A; López-Andujar R; Moya A; Pareja E; Montalva E; Yago M; de Juan M; Mir J; Prieto M
    Transplantation; 2010 Dec; 90(11):1204-9. PubMed ID: 21068701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C.
    Rayhill SC; Barbeito R; Katz D; Voigt M; Labrecque D; Kirby P; Miller R; Stolpen A; Wu Y; Schmidt W
    Transplant Proc; 2006 Dec; 38(10):3625-8. PubMed ID: 17175350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
    Stegall MD; Wachs ME; Everson G; Steinberg T; Bilir B; Shrestha R; Karrer F; Kam I
    Transplantation; 1997 Dec; 64(12):1755-60. PubMed ID: 9422416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.
    Wiesner RH; Shorr JS; Steffen BJ; Chu AH; Gordon RD; Lake JR
    Liver Transpl; 2005 Jul; 11(7):750-759. PubMed ID: 15973716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Status of liver and gastrointestinal transplantation at the University of Miami.
    Weppler D; Khan R; Fragulidis GP; Nery JR; Ricordi C; Tzakis AG
    Clin Transpl; 1996; ():187-201. PubMed ID: 9286568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
    Becker T; Foltys D; Bilbao I; D'Amico D; Colledan M; Bernardos A; Beckebaum S; Isoniemi H; Pirenne J; Jaray J;
    Transplantation; 2008 Dec; 86(12):1689-94. PubMed ID: 19104406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation.
    Iacob S; Cicinnati VR; Hilgard P; Iacob RA; Gheorghe LS; Popescu I; Frilling A; Malago M; Gerken G; Broelsch CE; Beckebaum S
    Transplantation; 2007 Jul; 84(1):56-63. PubMed ID: 17627238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.
    Klintmalm GB; Washburn WK; Rudich SM; Heffron TG; Teperman LW; Fasola C; Eckhoff DE; Netto GJ; Katz E
    Liver Transpl; 2007 Nov; 13(11):1521-31. PubMed ID: 17969201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
    Manrique A; Jiménez C; Ortega P; Abradelo M; Gimeno A; Calvo J; Cambra F; -Sterup RL; Morales JM; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2962-4. PubMed ID: 19010160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.